Equibles does not estimate personal net worth.
Get an email with a short summary when Regeneron Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get REGN alertsRobert Landry is recorded as CFO at Regeneron Pharmaceuticals, Inc. (REGN). The proxy statement of Regeneron Pharmaceuticals, Inc. reports total compensation of $8,298,455 for Robert Landry in fiscal 2021, including a base salary of $822,800. Disclosed compensation is on record for 5 fiscal years. Robert Landry has spoken on 6 earnings calls across 1 company, most recently for Regeneron Pharmaceuticals, Inc. on August 3, 2023. Regeneron Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Regeneron Pharmaceuticals, Inc. includes George D. Yancopoulos, M.D., Ph.D. (Chairman), Leonard S. Schleifer, M.D., Ph.D. (Chairman), Joseph J. LaRosa (General Counsel) and 7 others.
“My comments today on Regeneron's financial results and outlook will be on a non-GAAP basis unless otherwise noted. Regeneron's second quarter results demonstrate continued growth and strong financial performance across the organization.”
“My comments today on Regeneron's financial results and outlook will be on a non-GAAP basis unless otherwise noted. Regeneron performed well in the third quarter, with growth from key brands and execution across the business continuing to drive strong financial results on both the top and bottom line.”
“My comments today on Regeneron’s financial results and outlook will be on a non-GAAP basis unless otherwise noted.”
“My comments today on Regeneron’s financial results and outlook will be on a non-GAAP basis unless otherwise noted. Regeneron is off to a strong start in 2022 with double-digit top and bottom line growth in the first quarter, driven by execution across the business.”
“My comments today on Regeneron's financial results and outlook will be on a non-GAAP basis where applicable. In the third quarter, Regeneron once again delivered strong top and bottom line growth on increasingly diversified revenue streams, with contributions from REGEN-COV in our robust core business.”
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2021 | Regeneron Pharmaceuticals, Inc. (REGN) | Executive Vice President, Finance and Chief Financial Officer | $822,800 | $8,298,455 |
| 2020 | Regeneron Pharmaceuticals, Inc. (REGN) | Executive Vice President, Finance and Chief Financial Officer | $825,577 | $6,197,703 |
| 2019 | Regeneron Pharmaceuticals, Inc. (REGN) | Executive Vice President, Finance and Chief Financial Officer | $730,000 | $7,931,542 |
| 2018 | Regeneron Pharmaceuticals, Inc. (REGN) | Executive Vice President Finance and Chief Financial Officer | $680,000 | $9,356,619 |
| 2017 | Regeneron Pharmaceuticals, Inc. (REGN) | Executive Vice President, Finance and Chief Financial Officer | $618,000 | $4,794,736 |
